CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its trastuzumab biosimilar, Dazublys, used in the treatment of HER2-positive breast and gastric cancers. This approval follows the European Commission’s nod earlier in July, marking another significant milestone for the product.

Dazublys is the fourth biosimilar from CuraTeQ to be approved by the MHRA, after Bevqolva, Zefylti, and Dyrupeg, further strengthening the company’s growing oncology portfolio in regulated markets.

With this approval, CuraTeQ reinforces its strategic focus on biosimilars, particularly in oncology, as part of Aurobindo Pharma’s broader vision to expand its global footprint in biologics. The milestone also highlights the company’s commitment to delivering high-quality, affordable biologic therapies that can improve access to advanced cancer treatments worldwide.